Literature DB >> 21538527

Factors contributing to institutionalization in patients with Huntington's disease.

Adam Rosenblatt1, Brahma V Kumar, Russell L Margolis, Claire S Welsh, Christopher A Ross.   

Abstract

The objective of this study was to determine which factors are predictive of institutionalization in Huntington's disease. Seven hundred and ninety-nine subjects with 4313 examinations from the Baltimore Huntington's Disease Center were included in the data set; 88 of these patients with an average follow-up time of 9.2 years went from living at home to being institutionalized while being observed in our clinic. We examined demographic, genetic, and clinical variables for a relationship with institutionalization using linear regressions, a Cox proportional hazards model, and χ2 or t tests in certain cases. In our linear models, scores on the Quantified Neurologic Examination (R2=0.203, P<.001), Huntington's disease Activities of Daily Living Scale (R2=0.259, P<.001), and Motor Impairment Score (R2=0.173, P<.001) were found to have the strongest correlation with time until institutionalization. In addition, CAG repeat length (R2=0.248, P<.001) was significantly associated with disease duration at institutionalization, when controlling for age at onset. In the Cox proportional hazards model, scores on the Activities of Daily Living Scale, Mini-Mental State Examination, Quantified Neurologic Examination, and Motor Impairment Score all significantly predicted placement in long-term care. Finally, institutionalized patients were shown to have a higher CAG number and a lower level of educational attainment than patients who avoided institutionalization for at least 15 years after disease onset. Neurologic findings, functional capacity, cognitive impairment, and CAG repeat length are all likely determinants of institutionalization. In contrast with other dementing conditions like Parkinson's and Alzheimer's, psychiatric symptoms were not shown to predict institutionalization in Huntington's disease. This may illustrate the especially debilitating nature of the movement disorder of Huntington's disease in comparison with the other dementias.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21538527     DOI: 10.1002/mds.23716

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  8 in total

Review 1.  Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: There may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile.

Authors:  David C Rubinsztein; Harry T Orr
Journal:  Bioessays       Date:  2016-08-01       Impact factor: 4.345

Review 2.  Cognitive impairment in Huntington disease: diagnosis and treatment.

Authors:  Jane S Paulsen
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

3.  Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene.

Authors:  Peter K Panegyres; Chen-Chun Shu; Huei-Yang Chen; Jane S Paulsen
Journal:  J Neurol       Date:  2014-11-08       Impact factor: 4.849

4.  The progression rate of spinocerebellar ataxia type 3 varies with disease stage.

Authors:  Linliu Peng; Yun Peng; Zhao Chen; Chunrong Wang; Zhe Long; Huirong Peng; Yuting Shi; Lu Shen; Kun Xia; Vanessa B Leotti; Laura Bannach Jardim; Beisha Tang; Rong Qiu; Hong Jiang
Journal:  J Transl Med       Date:  2022-05-14       Impact factor: 8.440

Review 5.  Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction.

Authors:  Christopher A Ross; Alex Pantelyat; Jane Kogan; Jason Brandt
Journal:  Mov Disord       Date:  2014-09-15       Impact factor: 10.338

Review 6.  Palliative Care in Huntington Disease: Personal Reflections and a Review of the Literature.

Authors:  Christopher G Tarolli; Amy M Chesire; Kevin M Biglan
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-04-11

7.  Disparities in Palliative Care Utilization Among Hospitalized People With Huntington Disease: A National Cross-Sectional Study.

Authors:  Leonard L Sokol; Danny Bega; Chen Yeh; Benzi M Kluger; Hillary D Lum
Journal:  Am J Hosp Palliat Care       Date:  2021-07-22       Impact factor: 2.090

Review 8.  What do we know about Late Onset Huntington's Disease?

Authors:  Sai S Chaganti; Elizabeth A McCusker; Clement T Loy
Journal:  J Huntingtons Dis       Date:  2017
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.